ArticleFrontiers in medicine2026
Hyperuricemia in hospitalized patients with heart failure: prevalence and clinical correlates.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperuricemia frequently accompanies heart failure (HF), yet hospital-based real-world data from China remain insufficient. We therefore evaluated the burden of hyperuricemia in hospitalized patients with HF and explored its associated clinical correlates. Methods: We carried out a retrospective cross-sectional analysis of 1,985 patients admitted with HF. Hyperuricemia was defined as serum uric acid ≥ 7.0 mg/dL in males and ≥ 6.0 mg/dL in females. Candidate correlates were examined using univariable and multivariable logistic regression models. To further characterize the findings, we additionally applied restricted cubic spline analyses, and subgroup analyses by sex and age, and NYHA class. Results: The overall prevalence of hyperuricemia was 69.42%. Prevalence was similar across sex, age, and BMI groups, but differed by NYHA class. In the multivariable model, hyperuricemia was independently associated with markers of renal dysfunction, hemodynamic impairment, electrolyte imbalance, and metabolic disturbance. RCS analyses suggested nonlinear associations for potassium, BNP, eGFR, and HDL-C. Conclusion: Hyperuricemia was highly prevalent among hospitalized patients with HF and was associated with multiple markers of renal dysfunction, hemodynamic impairment, electrolyte imbalance, and metabolic disturbance. These findings provide real-world evidence suggesting that hyperuricemia in hospitalized HF patients may reflect a broader cardiorenal and metabolic profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.